• Je něco špatně v tomto záznamu ?

Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent Effect on DNA interactions, DNA adduct recognition and repair

H. Kostrhunova, J. Malina, AJ. Pickard, J. Stepankova, M. Vojtiskova, J. Kasparkova, T. Muchova, ML. Rohlfing, U. Bierbach, V. Brabec

. 2011 ; 8 (5) : 1941-54. [pub] 20110817

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022483

A combination of biophysical, biochemical, and computational techniques was used to delineate mechanistic differences between the platinum-acridine hybrid agent [PtCl(en)(L)](NO(3))(2) (complex 1, en = ethane-1,2-diamine, L = 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea) and a considerably more potent second-generation analogue containing L' = N-[2-(acridin-9-ylamino)ethyl]-N-methylpropionamidine (complex 2). Calculations at the density functional theory level provide a rationale for the binding preference of both complexes for guanine-N7 and the relatively high level of adenine adducts observed for compound 1. A significant rate enhancement is observed for binding of the amidine-based complex 2 with DNA compared with the thiourea-based prototype 1. Studies conducted with chemical probes and on the bending and unwinding of model duplex DNA suggest that adducts of complex 2 perturb B-form DNA more severely than complex 1, however, without denaturing the double strand and significantly less than cisplatin. Circular and linear dichroism spectroscopies and viscosity measurements suggest that subtle differences exist between the intercalation modes and adduct geometries of the two complexes. The adducts formed by complex 2 most efficiently inhibit transcription of the damaged DNA by RNA polymerase II. Not only do complexes 1 and 2 cause less distortion to DNA than cisplatin, they also do not compromise the thermodynamic stability of the modified duplex. This leads to a decreased or negligible affinity of HMG domain proteins for the adducts formed by either Pt-acridine complex. In a DNA repair synthesis assay the lesions formed by complex 2 were repaired less efficiently than those formed by complex 1. These significant differences in DNA adduct formation, structure, and recognition between the two acridine complexes and cisplatin help to elucidate why compound 2 is highly active in cisplatin-resistant, repair proficient cancer cell lines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022483
003      
CZ-PrNML
005      
20130324220219.0
007      
ta
008      
120806e20110817xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1021/mp200309x $2 doi
035    __
$a (PubMed)21806015
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kostrhunová, Hana. $7 _AN047101 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, vvi Kralovopolska 135, CZ-61265 Brno, Czech Republic.
245    10
$a Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent Effect on DNA interactions, DNA adduct recognition and repair / $c H. Kostrhunova, J. Malina, AJ. Pickard, J. Stepankova, M. Vojtiskova, J. Kasparkova, T. Muchova, ML. Rohlfing, U. Bierbach, V. Brabec
520    9_
$a A combination of biophysical, biochemical, and computational techniques was used to delineate mechanistic differences between the platinum-acridine hybrid agent [PtCl(en)(L)](NO(3))(2) (complex 1, en = ethane-1,2-diamine, L = 1-[2-(acridin-9-ylamino)ethyl]-1,3-dimethylthiourea) and a considerably more potent second-generation analogue containing L' = N-[2-(acridin-9-ylamino)ethyl]-N-methylpropionamidine (complex 2). Calculations at the density functional theory level provide a rationale for the binding preference of both complexes for guanine-N7 and the relatively high level of adenine adducts observed for compound 1. A significant rate enhancement is observed for binding of the amidine-based complex 2 with DNA compared with the thiourea-based prototype 1. Studies conducted with chemical probes and on the bending and unwinding of model duplex DNA suggest that adducts of complex 2 perturb B-form DNA more severely than complex 1, however, without denaturing the double strand and significantly less than cisplatin. Circular and linear dichroism spectroscopies and viscosity measurements suggest that subtle differences exist between the intercalation modes and adduct geometries of the two complexes. The adducts formed by complex 2 most efficiently inhibit transcription of the damaged DNA by RNA polymerase II. Not only do complexes 1 and 2 cause less distortion to DNA than cisplatin, they also do not compromise the thermodynamic stability of the modified duplex. This leads to a decreased or negligible affinity of HMG domain proteins for the adducts formed by either Pt-acridine complex. In a DNA repair synthesis assay the lesions formed by complex 2 were repaired less efficiently than those formed by complex 1. These significant differences in DNA adduct formation, structure, and recognition between the two acridine complexes and cisplatin help to elucidate why compound 2 is highly active in cisplatin-resistant, repair proficient cancer cell lines.
650    _2
$a akridiny $x chemie $x metabolismus $x farmakologie $7 D000166
650    _2
$a amidiny $x chemie $x metabolismus $x farmakologie $7 D000578
650    _2
$a antitumorózní látky $x chemie $x metabolismus $x farmakologie $7 D000970
650    _2
$a cisplatina $x analogy a deriváty $x chemie $x metabolismus $x farmakologie $7 D002945
650    _2
$a DNA $x chemie $x metabolismus $7 D004247
650    _2
$a adukty DNA $x chemie $7 D018736
650    _2
$a oprava DNA $x účinky léků $7 D004260
650    _2
$a B-DNA $x chemie $x metabolismus $7 D059371
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a protein HMGB1 $x metabolismus $7 D024243
650    _2
$a HeLa buňky $7 D006367
650    _2
$a lidé $7 D006801
650    _2
$a interkalátory $x chemie $x metabolismus $x farmakologie $7 D007364
650    _2
$a kinetika $7 D007700
650    _2
$a konformace nukleové kyseliny $x účinky léků $7 D009690
650    _2
$a organoplatinové sloučeniny $x chemie $x metabolismus $x farmakologie $7 D009944
650    _2
$a protein - isoformy $x metabolismus $7 D020033
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a thiomočovina $x chemie $x metabolismus $x farmakologie $7 D013890
650    _2
$a genetická transkripce $x účinky léků $7 D014158
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Malina, Jaroslav
700    1_
$a Pickard, Amanda J
700    1_
$a Štěpánková, Jana
700    1_
$a Vojtiskova, Marie
700    1_
$a Kašpárková, Jana, $d 1969- $7 xx0068609
700    1_
$a Muchova, Tereza
700    1_
$a Rohlfing, Matthew L
700    1_
$a Bierbach, Ulrich
700    1_
$a Brabec, Viktor, $d 1944- $7 jo20010087133
773    0_
$w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 8, č. 5 (20110817), s. 1941-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21806015 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120806 $b ABA008
991    __
$a 20130324220450 $b ABA008
999    __
$a ok $b bmc $g 944396 $s 779780
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 8 $c 5 $d 1941-54 $e 20110817 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
LZP    __
$a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...